Want to see ORIC full AI Analyst Report?
ORIC Stock Chart & Stats
$12.10
-$0.08(-0.66%)
At close: 4:00 PM EDT
$12.10
-$0.08(-0.66%)
Day’s Range― - ―
52-Week Range$7.23 - $14.93
Previous Close$11.8
Volume1.71M
Average Volume (3M)1.65M
Market Cap
$1.44B
Enterprise Value$908.34
Total Cash (Recent Filing)$264.76M
Total Debt (Recent Filing)$3.33M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Nov 09, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding103,652,660
10 Day Avg. Volume1,549,507
30 Day Avg. Volume1,650,377
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-6.30
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$21.56Price Target Upside78.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.51
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and roughly $381M of equity materially reduce default and refinancing risk for a clinical-stage biotech. This financial flexibility supports continued R&D and multi-year clinical programs, giving the company runway to advance trials without immediate revenue.
Progress To Late-stage Clinical TrialsAdvancing a program to global Phase 3 is a structural de-risking event for a biotech. A registrational trial raises the probability of eventual approval or partnering, diversifies clinical-stage assets, and creates durable value drivers beyond short-term market swings.
Stronger Governance And Compensation FrameworkTighter equity-plan governance and clear shareholder backing improve alignment with investors and reduce managerial discretion over dilution. This enhances long-term governance credibility and helps preserve shareholder value during future financings or strategic transactions.
Bears Say
No Revenues; Widening Net LossesAbsence of product revenue and expanding losses indicate the company remains pre-revenue and dependent on pipeline success. Persistent negative profitability limits internal funding capacity and raises execution risk if clinical outcomes or timelines slip.
Sustained Negative Cash FlowLarge, recurring negative operating and free cash flow mean the business relies on external financing to sustain trials. Even with improved FCF trends, ongoing cash burn increases the likelihood of future equity raises, altering capital structure and planning.
Increased Dilution Capacity From Equity PlansExpanded inducement and equity reserves provide hiring and M&A flexibility but raise structural dilution risk. For a cash-burning, pre-revenue biotech this amplifies shareholder dilution probability when capital is needed to fund late-stage trials or execute deals.
Oric Pharmaceuticals News
ORIC FAQ
What was Oric Pharmaceuticals Inc’s price range in the past 12 months?
Oric Pharmaceuticals Inc lowest stock price was $7.23 and its highest was $14.93 in the past 12 months.
What is Oric Pharmaceuticals Inc’s market cap?
Oric Pharmaceuticals Inc’s market cap is $1.44B.
When is Oric Pharmaceuticals Inc’s upcoming earnings report date?
Oric Pharmaceuticals Inc’s upcoming earnings report date is Nov 09, 2026 which is in 78 days.
How were Oric Pharmaceuticals Inc’s earnings last quarter?
Oric Pharmaceuticals Inc released its earnings results on Aug 03, 2026. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.359 by -$0.021.
Is Oric Pharmaceuticals Inc overvalued?
According to Wall Street analysts Oric Pharmaceuticals Inc’s price is currently Undervalued.
Does Oric Pharmaceuticals Inc pay dividends?
Oric Pharmaceuticals Inc does not currently pay dividends.
What is Oric Pharmaceuticals Inc’s EPS estimate?
Oric Pharmaceuticals Inc’s EPS estimate is -0.38.
How many shares outstanding does Oric Pharmaceuticals Inc have?
Oric Pharmaceuticals Inc has 103,652,660 shares outstanding.
What happened to Oric Pharmaceuticals Inc’s price movement after its last earnings report?
Oric Pharmaceuticals Inc reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.359. Following the earnings report the stock price went up 27.075%.
Which hedge fund is a major shareholder of Oric Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ORIC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oric Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.56 (78.15% Upside)
$21.56 (78.15% Upside)
Blogger Sentiment
Bullish
ORIC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.67%
Trailing 12-Months
Company Description
Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
ORIC Stock 12 Month Forecast
Average Price Target
$21.56
▲(78.15% Upside)
Technical Analysis
Spyre Therapeutics
―
Trevi Therapeutics
―
Praxis Precision Medicines
―
Pharming Group
―
Prime Medicine, Inc.
―
Ownership Overview
1.04% Insiders
15.44% Mutual Funds
16.79% Other Institutional Investors
52.85% Public Companies and
Individual Investors